"Interferons" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions.
| Descriptor ID |
D007372
|
| MeSH Number(s) |
D12.644.276.374.440 D12.776.467.374.440 D23.529.374.440
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Interferons".
Below are MeSH descriptors whose meaning is more specific than "Interferons".
This graph shows the total number of publications written about "Interferons" by people in this website by year, and whether "Interferons" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferons" by people in Profiles.
-
An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Cell. 2022 02 17; 185(4):614-629.e21.
-
Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma. Oncology. 2021; 99(5):310-317.
-
Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes. PLoS Pathog. 2019 01; 15(1):e1007532.
-
Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. J Acquir Immune Defic Syndr. 2016 11 01; 73(3):258-262.
-
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
-
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14.
-
IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late? Liver Int. 2012 Feb; 32 Suppl 1:74-8.
-
Current approach to the man with acute phase Peyronie's disease--case presentation and discussion. J Sex Med. 2011 Jun; 8(6):1556-8; quiz 1559.
-
Peyronie's disease: review of nonsurgical treatment options. Urol Clin North Am. 2011 May; 38(2):195-205.
-
Hepatitis C: current and future therapies. Mt Sinai J Med. 2008 Aug; 75(4):405-14.